• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Ardelyx (ARDX) Faces A Valuation Test, Is The Discount Too Wide?

    Simply Wall St·07/26/2026 10:21:06
    语音播报

    Why Ardelyx Stock Is Back in Focus

    Ardelyx (ARDX) is drawing fresh attention after recent market activity around its kidney disease and irritable bowel syndrome treatments, putting the stock under closer review for how the business fundamentals line up.

    See our latest analysis for Ardelyx.

    At a share price of US$5.03, Ardelyx has seen short term share price pressure, with the 30 day share price return down 9.37% and the year to date share price return down 18.21%. At the same time, the 1 year total shareholder return of 17.25% and 5 year total shareholder return of 189.08% point to a very strong longer term record, suggesting that recent moves may reflect shifting views on growth prospects and risk rather than a simple break in the story.

    If Ardelyx has put biopharma back on your radar, it could be a good moment to widen your watchlist with a fresh set of potential opportunities via 40 healthcare AI stocks

    Ardelyx now trades at a steep discount to both analyst targets and some intrinsic value estimates after its recent pullback. The real issue is whether that gap reflects mispricing or justified caution around profitability and risk.

    Most Popular Narrative: 69.2% Undervalued

    With Ardelyx trading at $5.03 against a widely followed fair value estimate of $16.33, the current price sits far below what this narrative implies.

    The rising prevalence of chronic kidney disease (CKD) and gastrointestinal disorders driven by an aging population continues to expand Ardelyx's core addressable markets, supporting sustained long-term demand for IBSRELA and XPHOZAH and driving future revenue growth. Recent and ongoing improvements in market access, prescription pull-through, and expansion of the sales force are boosting prescriber breadth and depth, contributing to accelerating product adoption and positioning the company to achieve strong topline growth and improved gross margins as fixed costs are leveraged.

    Read the complete narrative.

    Curious what has to happen for Ardelyx to justify that higher fair value estimate? The narrative leans on rapid revenue expansion, a sharp profit swing, and a richer future earnings multiple, all tied together under a single discount rate. The exact assumptions might surprise you.

    Result: Fair Value of $16.33 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Ardelyx still faces meaningful pressure from its concentrated reliance on IBSRELA and XPHOZAH, and from reimbursement uncertainty around Medicare coverage for XPHOZAH.

    Find out about the key risks to this Ardelyx narrative.

    Next Steps

    With both clear risks and real potential in the Ardelyx story, do you want to rely on others or test the data yourself and act while sentiment is still forming by weighing up the 4 key rewards and 1 important warning sign?

    Looking for more investment ideas beyond Ardelyx?

    If Ardelyx has sharpened your interest, do not stop here. Broadening your watchlist with new ideas can help you spot opportunities before the crowd does.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.